Allele granted NIH funds for Alzheimer’s treatment
As the most common cause of dementia, Alzheimer’s is a frequently encountered illness. Unfortunately, there are not any treatments that can stop or reverse the disease as it progresses in patients.
Allele’s scientists and academic collaborators have stated that there is a strong connection between Alzheimer’s and a new, uncharacterized target gene. This gene decreases beta-amyloid production and tau phosphorylation, which are both part of the plaque formations in Alzheimer’s. In addition, if this protein coagulates in the brain, it can inhibit synapses and cause cognitive impairment.
Using the NIH funds, Allele will create a panel of antibodies with this protein. The goal is to utilize these antibodies to develop a therapeutic drug candidate. Because of the size and shape of the antibodies, they can bypass the blood-brain barrier into difficult-to-reach brain regions. Each antibody can be altered to improve its therapeutic potential.
Allele’s researchers hope that this treatment will heighten the function of the antibody as it targets proteins found in Alzheimer’s patients’ brains. The overarching intention is to decrease the pathogenesis of Alzheimer’s to improve worldwide health.
Organizations in this story
Allele Biotechnology and Pharmaceuticals 6404 Nancy Ridge Dr San Diego, CA 92121-2248
National Institutes of Health 9000 Rockville Pike Bethesda, MD 20892